<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>De Santis F</submitter><pubmed_abstract>Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y&lt;sub>12&lt;/sub> inhibitor, anticoagulation, intravenous thrombolysi</pubmed_abstract><journal>Stroke</journal><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12829504</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians.</pubmed_title><pmcid>PMC12829504</pmcid><pubmed_authors>Foschi M</pubmed_authors><pubmed_authors>D'Anna L</pubmed_authors><pubmed_authors>Fischer U</pubmed_authors><pubmed_authors>Pontes-Neto OM</pubmed_authors><pubmed_authors>Turc G</pubmed_authors><pubmed_authors>Khatri P</pubmed_authors><pubmed_authors>Coutts SB</pubmed_authors><pubmed_authors>De Santis F</pubmed_authors><pubmed_authors>Sandset EC</pubmed_authors><pubmed_authors>Tsivgoulis G</pubmed_authors><pubmed_authors>Sacco S</pubmed_authors><pubmed_authors>Nasreldein A</pubmed_authors><pubmed_authors>Nguyen TN</pubmed_authors></additional><is_claimable>false</is_claimable><name>Acute Treatment of Disabling and Nondisabling Minor Ischemic Stroke: Expert Guidance for Clinicians.</name><description>Minor ischemic strokes, usually defined as acute ischemic strokes with National Institutes of Health Stroke Scale score ≤5, account for over half of all cases and are often underestimated due to initially mild symptoms. Yet up to 30% of patients develop disability within 90 days, challenging the notion of a benign course. This guidance offers a pragmatic, scenario-based framework for acute minor ischemic stroke management, considering symptom severity (disabling versus nondisabling), eligibility for reperfusion, and presence of large vessel occlusion. Drawing from randomized trials, real-world evidence, and international guidelines, we examine therapeutic strategies, including dual antiplatelet therapy with aspirin plus a P2Y&lt;sub>12&lt;/sub> inhibitor, anticoagulation, intravenous thrombolysi</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T22:05:18.109Z</modification><creation>2026-06-05T03:12:21.5Z</creation></dates><accession>S-EPMC12829504</accession><cross_references><pubmed>41376587</pubmed><doi>10.1161/STROKEAHA.125.053504</doi></cross_references></HashMap>